Eligard: leuprolide acetate in a novel sustained-release delivery system.
about
In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptideBiomedical Imaging in Implantable Drug Delivery Systems.Noninvasive characterization of in situ forming implants using diagnostic ultrasound.Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery.Nanopharmaceuticals (part 1): products on the market.Injectable long-acting systems for Radix Ophiopogonis polysaccharide based on mono-PEGylation and in situ formation of a PLGA depot.Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?Current advances in sustained-release systems for parenteral drug delivery.Pharmaceutical organogels prepared from aromatic amino acid derivativesExpert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.Review on Medusa:a polymer-based sustained release technology for protein and peptide drugs.In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system.Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.A novel ropivacaine-loaded in situ forming implant prolongs the effect of local analgesia in rats.Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.Role of in vitro release models in formulation development and quality control of parenteral depots.Nanomicellar formulations for sustained drug delivery: strategies and underlying principles.Injectable controlled release depots for large molecules.Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy.Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer.Effect of injection site on in situ implant formation and drug release in vivo.Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh.Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.Self-assembled drug delivery system based on low-molecular-weight bis-amide organogelator: synthesis, properties and in vivo evaluation.Injectable Polymers
P2860
Q28486215-C1F864CF-A614-471F-9309-D389C9EF8373Q30394673-0D050E77-993A-4A8D-98F8-0E1E59B17465Q30475791-7688D5C6-9CC3-4C74-A4F7-45472D6216B5Q33794267-90254669-15F7-4990-8A74-EE2AB6B109FBQ34230175-F44E30F3-A4A3-4720-98C8-0F988062EB4EQ34637435-0E3B2CF8-20C9-4EE9-AE1A-FDA736767447Q34922985-D16AD099-AC2C-4D78-9FC9-38B3E07F05C9Q36235541-0BB9F202-EC7C-4F65-A8F0-7F5385EC2E95Q36316931-CA3E8FB5-50F1-4F32-80A3-0BEEBA3DEDFAQ36808501-5D3A10F5-E063-448F-BA83-84031C436110Q36861017-331C6AFF-3606-4652-A7CB-EFE36CA96A33Q36903816-633D14AE-866A-40E8-AB94-9E03208C61FDQ37079242-98FE47E1-C089-4167-A256-F2E69EC68B43Q37115994-99F59871-7918-44F5-B593-3EF57A8ADE86Q37180066-998D6F22-B124-491D-834A-0B965D575BCAQ37478907-7C625DDD-6E19-47F1-A4CF-69CD98EB54A7Q37639309-465246A9-63B1-49C8-8DEB-BA12F0FC807EQ37731548-98B3F056-A2FC-4967-91CF-EEEA1BE758C4Q38220192-B3066E93-2DB1-487E-BE06-20AE87A43020Q38539324-5461E24C-A257-4281-A1AA-04E1CA31A179Q38555085-B5E08E79-B869-45A1-B26E-4A672146DB7EQ39398234-1234E547-D88F-4269-9A63-2F17DA89FBFDQ39664876-7A753CC4-3D94-4485-8FDC-C6C2E7977501Q42152277-7380DCC0-B561-42E4-B4E2-38F6965A836AQ42412753-00FD9537-83F5-4FC0-95C1-C54827101921Q42677388-FFADBE29-09A2-4DFB-8E82-625BAD957391Q47323039-55CC03E6-4C91-4C35-896B-61B742442CA0Q57341085-D2E80655-7A43-4E44-B0C3-9416C6BE3B9A
P2860
Eligard: leuprolide acetate in a novel sustained-release delivery system.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@ast
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@en
type
label
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@ast
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@en
prefLabel
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@ast
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@en
P1433
P1476
Eligard: leuprolide acetate in a novel sustained-release delivery system.
@en
P2093
Oliver Sartor
P356
10.1016/S0090-4295(02)02396-8
P407
P433
P577
2003-02-01T00:00:00Z